医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

ニュース
添付文書
薬の臨床実感＆助言集

Takeda Receives Positive CHMP

Takeda Receives Positive CHMP Opinion Recommending Approval of Dengue Vaccine Candidate in EU and Dengue-Endemic Countries

Takeda Receives Positive CHMP Opinion Recommending Approval of Dengue Vaccine Candidate in EU and Dengue-Endemic Countries

バイオテクノロジーヘルスケアヘルス一般腫瘍学臨床試験製薬　 TimeLine: Opinion Recommending Approval of Dengue Vaccine Candidate in EU and Dengue-Endemic Countries Takeda Receives Positive CHMP

2022年10月14日

$Takeda Receives Positive CHMP Opinion for Maribavir for the Treatment of Adults with Post-transplant Cytomegalovirus (CMV) Refractory (With or Without Resistance) to Prior Therapies$

Takeda Receives Positive CHMP Opinion for Maribavir for the Treatment of Adults with Post-transplant Cytomegalovirus (CMV) Refractory (With or Without Resistance) to Prior Therapies

バイオテクノロジーヘルスケア幹細胞感染症臨床試験製薬　 TimeLine: CMV Refractory Takeda Receives Positive CHMP

2022年09月16日

Takeda Receives Positive CHMP Opinion for Vedolizumab IV for the Treatment of Active Chronic Pouchitis

Takeda Receives Positive CHMP Opinion for Vedolizumab IV for the Treatment of Active Chronic Pouchitis

バイオテクノロジーヘルスケアマネージド・ケア医療機器医療用品外科臨床試験製薬遺伝学　 TimeLine: Opinion for Vedolizumab IV for the Treatment of Active Chronic Pouchitis Takeda Receives Positive CHMP

2021年12月18日

Takeda Receives Positive CHMP Opinion for Pre-Filled Syringe Presentation of TAKHZYRO® (lanadelumab) for Use as a Preventive Treatment for Hereditary Angioedema Attacks

Takeda Receives Positive CHMP Opinion for Pre-Filled Syringe Presentation of TAKHZYRO® (lanadelumab) for Use as a Preventive Treatment for Hereditary Angioedema Attacks

バイオテクノロジーヘルスケア製薬遺伝学　 TimeLine: lanadelumab Opinion for Pre-Filled Syringe Presentation of TAKHZYRO Takeda Receives Positive CHMP

2020年05月29日

Takeda Receives Positive CHMP Opinion for ADCETRIS® (brentuximab vedotin) in Combination with CHP (Cyclophosphamide, Doxorubicin and Prednisone) for Treatment of Adult Patients with Previously Untreated Systemic Anaplastic Large Cell Lymphoma

Takeda Receives Positive CHMP Opinion for ADCETRIS® (brentuximab vedotin) in Combination with CHP (Cyclophosphamide, Doxorubicin and Prednisone) for Treatment of Adult Patients with Previously Untreated Systemic Anaplastic Large Cell Lymphoma

バイオテクノロジーヘルスケア腫瘍学臨床試験製薬　 TimeLine: ADCETRIS Brentuximab Vedotin Cyclophosphamide Opinion for Takeda Receives Positive CHMP

2020年03月31日

Takeda Receives Positive CHMP Opinion for ALUNBRIG® (brigatinib) as a First-Line Treatment for ALK+ Non-Small Cell Lung Cancer

Takeda Receives Positive CHMP Opinion for ALUNBRIG® (brigatinib) as a First-Line Treatment for ALK+ Non-Small Cell Lung Cancer

バイオテクノロジーヘルスケア腫瘍学臨床試験製薬　 TimeLine: ALUNBRIG as a First-Line Treatment for ALK+ Non-Small Cell Lung Cancer brigatinib Opinion for Takeda Receives Positive CHMP

2020年03月02日

Takeda Receives Positive CHMP Opinion for Subcutaneous Formulation of Vedolizumab for use as Maintenance Therapy in Adults with Moderately to Severely Active Ulcerative Colitis or Crohn’s Disease

Takeda Receives Positive CHMP Opinion for Subcutaneous Formulation of Vedolizumab for use as Maintenance Therapy in Adults with Moderately to Severely Active Ulcerative Colitis or Crohn’s Disease

バイオテクノロジーヘルスケア臨床試験製薬　 TimeLine: Opinion for Subcutaneous Formulation of Vedolizumab for use as Maintenance Therapy in Adults with Moderately to Severely Active Ulcerative Colitis or Crohn’s Disease Takeda Receives Positive CHMP

2020年02月28日